Stock Price

With triple-digit growth, the firm's partner-led model is dominating the market as companies race to defend against escalating third-party cyber threats.

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

As a wave of old solar panels looms, Comstock Inc. is betting on a certified zero-landfill recycling facility. Can this green venture save its financials?

Rapid7's 2026 awards reveal a shift in cybersecurity, where partners are no longer just resellers but crucial allies in the global, AI-driven fight.

Insight Molecular Diagnostics secures $26M to expand its transplant rejection test to the heart market, backed by a major shareholder amid market dilution concerns.

HeartCore Enterprises forecasts a dramatic swing to profitability in 2025 after divesting its software unit, betting its future on IPO consulting.

Exodus reports a surge in users and swap volume for January, defying a market downturn while strategically increasing its Solana treasury holdings.

With major conferences ahead, clinical-stage MBX Biosciences aims to impress investors with its promising peptide therapies for endocrine and metabolic disorders.

The asset manager starts 2026 with a bang, fueled by massive European inflows, a strategic shift to higher-fee products, and resilient digital asset growth.

The digital bank posted 45% net income growth and a 36% credit surge, proving rapid expansion and profitability can coexist in Latin America's fintech wars.

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

Terex declared a steady dividend, but the real story is its surging stock and a bold forecast, revealing deep confidence in its strategic direction.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

With French state backing, Eutelsat secures €1bn to build its next-gen OneWeb LEO constellation, intensifying the global satellite internet race.

With a massive French state-guaranteed financing, Eutelsat is funding a new fleet of 340 Airbus satellites to secure OneWeb's future in the LEO race.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

Frequency Holdings (OTC: FRQN) plants its flag at 14 Wall Street, a high-stakes play for 'optics and access' amid a volatile market position.

A major new report reveals a deepening crisis in rural healthcare, as a $50 billion federal program clashes with devastating cuts, pushing a vital system to the brink.